Objective-To analyse the cost-benefit of screening for and antihypertensive treatment of early renal disease indicated by microalbuminuria in patients with insulin dependent diabetes mellitus.
albumin excretion and probably postpones or prevents clinical nephropathy. We therefore carried out a simulation study of the likely long term outcome of a programme of screening and antihypertensive intervention for microalbuminuria in patients with insulin dependent diabetes mellitus. We aimed firstly to estimate the effectiveness in terms of survival and need for kidney transplantation and the incidence of overt diabetic nephropathy, and secondly to estimate the efficiency of a screening programme by looking at all direct costs and savings.
We used the results from previous epidemiological studies of the incidence of diabetic nephropathy, the mortality of patients with and without diabetic nephropathy,'8 and observational data regarding the rate of progression of microalbuminuria. The long term effect of antihypertensive treatment was set at three different levels due to lack of long term experience in patients with microalbuminuria.
Methods
The flow chart in figure 1 shows the different stages from onset of diabetes until death. Each lambda (X) represents the hazard function for progression or death at each stage adjusted for sex, age, and duration of diabetes. These hazard functions were estimated from Introduction Without intervention diabetic nephropathy develops in one third of all patients with insulin dependent diabetes mellitus and is a major threat to their survival and quality of life.' 2 These patients are characterised by increased mortality,34 increased risk of proliferative retinopathy,56 and increased morbidity and mortality due to vascular disease.78 Diabetic nephropathy leads to progressive loss of renal function and will necessitate dialysis or transplantation in most cases. Microalbuminuria (defined as urinary albumin excretion rate of sive treatment in the case of microalbuminuria and nephropathy, costs of dialysis, costs of kidney transplantation, and costs of immunosuppressive agents in cases of transplantation (table I). All costs were based on the 1991 prices in Germany as reimbursed by the sickness funds, and the economical analysis was carried out from the point of view of the German sickness fund. A broader viewpoint would certainly show greater benefits, especially to society. Most of the savings, however, would not occur with the financier who pays most of the costs-the sickness funds-but with the govemment and employers. Furthermore, indirect costs (for example, loss of working capacity due to dialysis) and indirect savings (for example, increased number of active years of work) are influenced by variable factors such as educational level, rate of unemployment, etc. Costs due to potential side effects of the antihypertensive treatment were not included in the analysis but severe side effects are rare with the antihypertensive treatment suggested here. As the calculations were based only on direct costs and savings the present study underestimates the total savings associated with the screening programme. The number of visits to diabetes centres was assumed not to be affected by the programme as urinary albumin excretion was measured only once a year and thus could be done at a routine consultation.
As the costs (and saved costs) will occur at different points in time discounting of the cash flow was necessary to make the economic consequences of the altemative programmes comparable. The calculations were performed with two different real discount rates: 2-5% and 6% a year, respectively.
All costs and savings are given in deutschmarks (DM) according to the recommendations of the Organisation for Economic Cooperation and Development as the calculations of costs and savings were based on the German sickness fund subsidiaries.
Results
Incidence of nephropathy and end stage renal failure- Table II shows the estimated effect of antihypertensive treatment on the rate of increase of urinary albumin excretion and on the duration from onset of microalbuminuria to nephropathy. Onset of nephropathy would be delayed by six years, assuming an effect of 33%, while a 67% effect would delay onset by 24 years. Because of the delayed onset of nephropathy the patients would be older when developing nephropathy. Thus some of the patients would die from other natural causes or diseases before entering end stage renal failure. The need for kidney transplantation or dialysis would therefore decrease by 21% and 63% assuming an effect of treatment of 33% and 67%, respectively.
Mortality- Figure 2 shows the median life expectancy for the subgroup of patients developing microalbuminuria. The median life expectancy increased by four to 14 years, and the effect was greatest in patients who developed diabetes during childhood. As only one out of three patients would develop diabetic nephropathy the increase in median life expectancy was lower when calculated on the entire cohort (two to five years). The increase in life expectancy was 50% higher in patients developing diabetes before the age of 5 years than in patients developing diabetes after the age of 25 years.
Costs and savings- Figure 3 shows the relation between real discount rate, treatment efficacy, and net savings. Each discount rate of 6% an effect of 1 1% of the antihypertensive treatment would be needed to balance costs and savings. With a real discount rate of 2-5% an 8% effect would be needed. Thus, reducing the annual rate of increase of albuminuria from 20 to 18% would balance costs and savings. Figure 4 shows the net savings for two different levels of treatment effect and two differ-"f_ ent discount rates. The savings per patient would range 100% from DM 1500 ($800) (real discount rate of 6%, effect rtensive of treatment of 33%) and DM 11 000 ($7700) (real discount rate of 2-5%, effect of treatment of 67%). decreased considerably (60-70%) by treatment with antihypertensive drugs '3 "" and that strict metabolic control"' and antihypertensive treatment seems to reduce the progression of microalbuminuria,'6 17 although long term data are still lacking.
Initiating a screening programme is, however, both expensive and time consuming. Furthermore, screening programmes should be initiated only if they benefit patients (survival or quality of life) or society (health care costs). It is necessary to decide on priorities between programmes, and setting different programmes in order of priority raises the need for evaluation of efficiency for each programme.
In accordance with a recent American study23 the present analysis showed that an intervention programme which includes screening for microalbuminuria and early treatment with antihypertensive drugs would be neutral with respect to costs and savings if antihypertensive treatment could reduce the annual increase in the rate of albumin excretion by 8 to 10% (from 20 to 18% a year). The programme would offer considerable life saving and a reduced incidence of end stage renal failure at treatment effects of 33% and 67%.
In the present design screening for albuminuria was performed on an annual basis. If one urine sample screened showed microalbuminuria, testing should be repeated twice to confirm the diagnosis.26 Annual screening was chosen on the basis of a likely increase in the rate of urinary albumin excretion of 20% a year and a day to day variability between individual patients of 40%./7 More frequent testing is unnecessary as the patients are likely to remain in the lowest range of microalbuminuria (20-60pLg/min) for a period of six years. 28 The intervention used in this programme was antihypertensive treatment, which has proved effective in patients with diabetic nephropathy. Two different studies have shown that the rate of decline in the rate of glomerular filtration is reduced by about 60/ 70% by antihypertensive drugs.'3 14 In concordance with this Mathiesen et al found that the eight year survival of patients with nephropathy increased from 49% to 87% after the introduction of antihypertensive drugs. '5 In patients with microalbuminuria it is still unknown whether antihypertensive drugs affect the long term prognosis (that is, risk of developing end stage renal failure and mortality). Microalbuminuria can be lowered (and in several cases normalised) by antihypertensive drugs, and several studies (table III) have consistently shown that antihypertensive drugs reduce microalbuminuria in patients with insulin dependent diabetes. Most of these studies were small and of short duration (one to two years). In the only pen long term study (four years' duration) a considerable number of patients in the control group developed proteinuria and an associated decline in the glomerular filtration rate whereas this was not seen in the group treated with angiotensin converting enzyme inhibitors. '7 This protective effect of treatment with angiotensin converting enzyme inhibitors was recently confirmed in a multicentre controlled clinical trial. 29 In patients with an albumin excretion rate between 20 and 200 ,ug/min, four out of 44 actively treated patients progressed to clinical nephropathy whereas this was the case in 12 out of 44 controls. The annual rate of increase of the albumin excretion rate was reduced from 18-3% to 2-1% by captopril. As development of proteinuria is consistently associated with a fall in glomerular filtration rate the reduction or stabilisation in microalbuminuria will probably preserve renal function.2830 Antihypertensive treatment in microalbuminuria is therefore likely to postpone considerably the development of proteinuria and to postpone or prevent development of end stage renal failure.
In patients with diabetic nephropathy the clinical effect of antihypertensive drugs seems to be a 60-70% reduction in the rate of decline of the glomecular filtration rate. In patients with microalbuminuria the precise effect cannot be estimated on the basis of the present studies, but in the study by Mathiesen et al 30% of the control group developed overt nephropathy compared to none in the actively treated group,'7 and in the multicentre trial the control group was three times more likely to develop overt nephropathy than the actively treated group (30% versus 10%). 29 The risks of developing nephropathy and mortality rates were calculated from the previously published Danish cohort study of 2890 patients with insulin dependent diabetes.'8 Information regarding microalbuminuria was not available as the study covered a period when tests for microalbuminuria had not yet been developed. Thus the observed mortality for patients without nephropathy in that study included patients with normal albuminuria as well as microalbuminuria. More recent studies of patients with noninsulin dependent diabetes3' and subjects without diabetes32 show a clear excess mortality in patients with microalbuminuria, predominantly due to cardiovascular disease. Whether this is also the case in patients with insulin dependent diabetes is unknown. If there is an excess mortality in patients with insulin dependent diabetes and microalbuminuria, irrespective of intervention, our analysis would overestimate the true effect on survival. The costs and the benefits are, however, not affected by this as we have not included the increased life expectancy in our economic analysis.
In conclusion we have shown that establishment of screening programmes for microalbuminuria for all patients with insulin dependent diabetes would be economically neutral at a treatment effect of 1O0%. With an estimated treatment effect of 33% to 67% the screening and intervention programme would lead to substantial increases in life expectancy and reduction in the incidence of end stage renal failure. We therefore recommend a screening programme for all patients with insulin dependent diabetes, including annual measurement of urinary albumin excretion rate. Based on the data from intervention studies we would also recommend that very early antihypertensive treatment be carefully considered. Screening programmes should be established with the purpose of monitoring the effects and the efficiency of the programme.
